Cargando…
Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects
Treatment-resistance in schizophrenia remains a public health problem: about 20% to 30% of patients do not respond to antipsychotic therapy. Clozapine has been shown to be effective in about one-third of patients, but the medical risks and weekly blood tests limit its broad application. While the he...
Autores principales: | Ackenheil, Manfred, Weber, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181786/ https://www.ncbi.nlm.nih.gov/pubmed/22034253 |
Ejemplares similares
-
Developments in antipsychotic therapy with regard to hypotheses for schizophrenia
por: Ackenheil, Manfred, et al.
Publicado: (2002) -
The therapeutic transnosological use of psychotropic drugs
por: Ackenheil, Manfred, et al.
Publicado: (1999) -
Pharmacogenomics in depression and antidepressants
por: Bondy, Brigitta
Publicado: (2005) -
Immunological aspects of the treatment of depression and schizophrenia
por: Müller, Norbert
Publicado: (2017) -
DNA methylation and demethylation as targets for antipsychotic therapy
por: Guidotti, Alessandro, et al.
Publicado: (2014)